Page 43 of 95
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

11-05 :: May/June 2011

nanotimes

Companies Facts

using 30nm class four gigabit (Gb) DDR3 DRAM chips.Samsung’s 30nm-class 4Gb DDR3 chip offers an approximate 50% increase in productivity over a 40nm-class 4Gb DDR3, and as a result is expected to achieve rapid market penetration. Samsung started producing monolithic 4Gb DDR3 DRAM devices based on 30nm-class technology in February, which is only one year after it started producing 40nm-class 4Gb DDR3 DRAM devices. Just two months later, it began to provide 16GB modules to a number of server system manufacturers. http://www.samsung.com/GreenMemory

Solazyme is offering 10,375,000 shares, and selling stockholders are offering 600,000 shares. Head- quartered in South San Francisco, USA, Solazyme, Inc. is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. http://www.solazyme.com

S

tarpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) announced successful results

of a major phase 2 clinical study that demonstrated efficacy of VivaGel® vaginosis (BV).

for the treatment of bacterial Key Points: • VivaGel® • VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV; expected to avoid many shortcomings of existing therapies;

• Trial results support new patent filing which extends VivaGel®

S

olazyme‘s shares begun trading on the NASDAQ Global Select Market on May 27, 2011 under the ticker symbol “SZYM”.

In May 2011, the Compa- ny announced the pricing of its initial public offering of 10,975,000 shares of common stock at a price to the public of $18.00 per share. Of the shares of com- mon stock in the offering,

• BV prevention trial of VivaGel® 2011;

protection to at least 2032;

• Planning underway for Phase 3 trials for VivaGel® for BV treatment;

to commence Q3

• Addressable global market for BV treatment and prevention potentially exceeds $1B.

In May, Starpharma Holdings has signed a licence agreement with Okamoto Industries Inc (TSE: JP3192800005) in relation to the VivaGel®

43

-coated

condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market. http://www.starpharma.com

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95